STRATIFY; Near-infrared fluorescence molecular imaging of adalimumab-800CW to elucidate the drug distribution throughout inflamed tissue in inflammatory bowel disease and rheumatoid arthritis

2024-513390-50-00 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 6 Aug 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 33
Countries 1
Sites 1

Crohn's disease

Key facts

Sponsor
Universitair Medisch Centrum Groningen
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
6 Aug 2024 → ongoing
Decision date (initial)
2024-10-03
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-513390-50-00
EudraCT number
2020-004405-31
ClinicalTrials.gov
NCT03938701

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Crohn's disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10058338 Spondylarthritis 10028395
20.1 PT 10021972 Inflammatory bowel disease 100000004856
23.1 LLT 10003268 Arthritis rheumatoid 10028395

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Groningen

Sponsor organisation
Universitair Medisch Centrum Groningen
Address
Hanzeplein 1
City
Groningen
Postcode
9713 GZ
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
W.B. Nagengast

Public contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
W.B. Nagengast

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 33 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
University Medical Center Groningen
Department of Gastroenterology and Hepatology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-08-06 2024-08-22

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-20 Netherlands Acceptable with conditions
2024-10-03
2024-10-03
2 SUBSTANTIAL MODIFICATION SM-2 2025-04-25 Netherlands Acceptable
2025-07-16
2025-07-16
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-08-04 Netherlands Acceptable
2025-07-16
2025-08-04